サンプル依頼リスト カート
  • English
  • Korean
表紙：赤痢菌感染症の世界市場-2023年～2030年
市場調査レポート
商品コード
1352184

赤痢菌感染症の世界市場-2023年～2030年

Global Shigella Infections Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
赤痢菌感染症の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

赤痢は、赤痢菌と呼ばれる細菌の一種が引き起こす食中毒です。赤痢は、嘔吐、発熱、下痢（時に血便）、腹痛などの症状を特徴とします。感染経路は通常、糞口感染で、不衛生な生活習慣、汚染された水や食品、混雑した生活環境などが原因となることが多いです。

診断、治療、予防に重点を置く医療・製薬業界が、赤痢菌感染症市場を独占しています。赤痢菌感染症の治療薬を製造する製薬企業、診断ツールのプロバイダー、病気の蔓延を食い止めるための公衆衛生活動など、すべてがこの分野に含まれます。

ダイナミクス

赤痢菌感染症の有病率の増加

2023年にInternational Journal of Molecular Sciencesが発表した論文によると、赤痢菌症は、汚染された食品や水の摂取を通じて、複数の赤痢菌によって広がる一般的な感染症であり、豊かな国でも発展途上国でも公衆衛生の課題となっています。しかし、人から人への感染により、赤痢菌症の発生率は同性愛の男性でも顕著に高いです。結腸、回腸、直腸の上皮細胞が侵入し、それが原因となります。赤痢菌感染症は年齢に関係なく罹患する可能性がありますが、感受性の強い集団では他の集団よりも多くの患者が発生しています。

世界中で、下痢性疾患は毎年100万人以上の死亡原因となっています。しかし、赤痢菌症は特に幼児において、年間164,000人以上の死亡の原因となっていると考えられています。また、赤痢菌は年間約1億2,500万件の下痢の原因とも考えられています。赤痢菌症は世界中の人々に感染し、公衆衛生上の問題に加え、深刻な経済的損失をもたらしています。

ワクチン開発

赤痢菌は、赤痢症として知られる腸内感染症の原因菌です。下痢、発熱、腹痛、腸が空でも便をしたくなるなどの症状が、通常、接触後1～2日で現れます。赤痢菌の大部分は抗生物質耐性を獲得します。世界保健機関（WHO）は、認可されたワクチンがないため、有効な赤痢菌ワクチン候補の開発を公衆衛生上の優先事項とみなしています。

ナノテクノロジーを用いてワクチンの特異性と効力を高めることにより、その開発において特別な役割を果たします。抗原は500ナノメートル以下のナノ粒子を容易に吸収するため、アジュバントやワクチン抗原の送達に適したキャリアとなります。抗原／アジュバントは、抗原の安定性の向上、標的投与、長期放出などの利点を得るために、ナノ粒子の中に封入されるか、表面に装飾されます

新しい抗生物質の開発ニーズの増加

獣医療においても健康管理においても、ヒトは非常に多くの抗生物質を使用しているため、一般に病原性細菌の薬剤耐性が増加しています。現在の治療法では、すべての細菌を完全に根絶することはほとんどなく、一部の細菌は生き残り、耐性遺伝子を増殖させます。

さらに、抗生物質に耐える遺伝資源を開発した細菌は、近縁種の細菌であっても互いにその資源を交換することができます。このため、薬剤耐性の高い赤痢菌は憂慮すべき存在です。このような事態を食い止めるためには、この種の感染症を治療するための新しい抗生物質を開発する必要があります。

啓発と教育

赤痢菌感染症の予防と治療には、啓発と教育が不可欠です。人々や地域社会は、効果的なコミュニケーションと教育活動によって、赤痢菌の危険性、感染様式、予防法をよりよく理解することができます。手指衛生、安全な食品の取り扱い、清潔な水源の重要性は、啓発キャンペーンで強調することができます。赤痢菌の蔓延は、適切な手洗いの方法と食品の安全手順を指導することで防ぐことができます。

例えば、2022年にはアジアで1つの会議が開催され、新しい取り組みや困難、赤痢菌のような腸内細菌性疾患、疫学、負担、肝炎を含む他のウイルス感染症に対するワクチン接種、さらにCOVIDパンデミック時の下痢に関する調査から得られた教訓などがトピックとして取り上げられました。

抗生物質耐性

赤痢菌感染症だけでなく、感染症という大きな分野において、抗生物質耐性は大きな懸念事項です。赤痢菌のような細菌が、かつては感染症の治療に有効であった抗生物質にさらされているにもかかわらず、生き残り増殖する能力を獲得した場合、この現象は抗生物質耐性として知られています。一般的な抗生物質がこの耐性によって効かなくなり、感染症の治療が困難になり、生命を脅かす病気や合併症、さらには死に至る危険性が高まります。

処方箋なしに抗生物質を服用したり、推奨されたコースをスキップしたりするような抗生物質の誤用は、耐性の出現を早める可能性があります。赤痢菌感染症は歴史的に過剰な抗生物質治療を受けてきたため、耐性菌の出現を促してきました。

ワクチン開発の課題

菌の性質と菌が引き起こす病気のため、赤痢菌感染症のワクチン開発は困難です。進歩はしているもの、こうした困難が効率的なワクチン開発の難易度を高めています。赤痢菌はその表面抗原に基づき、様々な血清型に分類されます。ある血清型に免疫しても別の血清型に対する交差防御が得られないことがあるため、すべての血清型に対する包括的な防御を提供するワクチンを開発することは困難です。

また、自然感染や予防接種後に長期間の免疫を獲得することは困難です。予防接種の中には、防御免疫を促進するという点で、有効期限が限られているものもあり、効果を得るためには補充接種が必要です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 赤痢菌感染症の有病率の増加
      • ワクチン開発
      • 新しい抗生物質の開発ニーズの増加
      • 啓発と教育
    • 抑制要因
      • 抗生物質耐性
      • ワクチン開発の課題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 薬剤クラス別

  • シプロフロキサシン
  • アジスロマイシン
  • その他

第8章 タイプ別

  • 志賀赤痢菌腸炎菌
  • フレキシネル菌
  • ボイド菌
  • ソンネ菌

第9章 投与経路別

  • 注射薬
  • 経口薬
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Emergent BioSolutions, Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Pfizer, Inc.
  • Aurobindo Pharma
  • LimmaTech Biologics AG
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Mylan N.V.
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila

第14章 付録

目次
Product Code: PH6951

Overview

Shigellosis is a foodborne sickness that can be brought on by a genus of bacteria called Shigella. Shigellosis is characterized by symptoms like vomiting, fever, diarrhea (sometimes bloody), and abdominal pain. The infection is typically spread by the fecal-oral route, which is frequently brought on by poor hygiene habits, tainted water or food, and crowded living situations.

With an emphasis on diagnosis, treatment, and prevention, the healthcare and pharmaceutical industries dominate the market for Shigella infections. Pharmaceutical businesses that make medications to treat Shigella infections, diagnostic tool providers, and public health activities to stop the disease's spread are all included in this sector.

Dynamics

Increasing Prevalence of Shigella Infections

As per the article published by the International Journal of Molecular Sciences in 2023, shigellosis is a common infectious disease spread by several Shigella species through the intake of tainted food and water, and it is a challenge for both rich and developing nations' public health. But due to person-to-person transmission, the incidence of shigellosis is also notably high in homosexual males. Epithelial cells from the colon, ileum, and rectum invade, which is what causes it. Shigella infections can affect persons of any age, but sensitive populations have seen more cases than others.

Worldwide, diarrheal illnesses are responsible for more than a million fatalities each year. However, shigellosis is thought to be responsible for over 164,000 annual deaths, particularly in young children. Shigella species are also thought to be responsible for about 125 million cases of diarrhea each year. Shigellosis affects people all around the world and causes serious economic losses in addition to public health issues.

Vaccine Development

Shigella bacteria are the source of the intestinal infection known as shigellosis. Diarrhea, fever, abdominal pain, and the need to pass feces even when the bowels are empty are among the symptoms that typically appear one to two days after contact. The majority of Shigella strains develop antibiotic resistance. The World Health Organization (WHO) has deemed developing an effective Shigella vaccine candidate to be a public health priority due to the lack of an authorized vaccine.

By enhancing the specificity and potency of vaccines using nanotechnology, it plays a special role in their development. Antigens easily absorb nanoparticles smaller than 500 nanometers, making them suitable carriers for the delivery of adjuvants and vaccination antigens. Antigens/adjuvants are either enclosed within or embellished on the surface of nanoparticles for their benefits, which include increased antigen stability, targeted administration, and long-term release.

Increasing Need to Develop New Antibiotic

Because human use so many antibiotics in both veterinary medicine and their health care, they are generally observing an increase in drug resistance in pathogenic bacteria. Current therapies seldom completely eradicate all bacteria, some survive and propagate their resistance genes, overusing antibiotics results in the development of resistance mechanisms.

Furthermore, bacteria that have developed the genetic resources to withstand antibiotics can trade these resources with one another, even with bacteria from closely related species. These highly drug-resistant Shigella strains are alarming because of this. To stop this there is a need to develop new antibiotics solutions to treat these types of infections.

Awareness and Education

To prevent and treat Shigella infections, awareness and education are essential. People and communities can better grasp the dangers, modes of transmission, and preventative actions connected with shigellosis with the use of effective communication and education efforts. The significance of good hand hygiene, safe food handling, and clean water sources can be emphasized in awareness campaigns. Shigella germs can be prevented from spreading by instructing individuals on proper hand-washing techniques and food safety procedures.

For instance, in 2022, One meeting was held in Asia, where topics included new initiatives and difficulties, enteric bacterial illnesses like Shigella spp., epidemiology, burden, and vaccinations against other viral infections including hepatitis, as well as the lessons learned from research on diarrhea during the COVID pandemic.

Antibiotic Resistance

In the context of Shigella infections as well as the larger field of infectious illnesses, antibiotic resistance is a major concern. When bacteria, like Shigella, acquire the ability to survive and proliferate in spite of exposure to antibiotics that were once successful in treating infections, this phenomenon is known as antibiotic resistance. Common antibiotics may no longer be effective due to this resistance, making infections harder to treat and raising the risk of life-threatening sickness, complications, and even death.

Antibiotic misuse, such as taking them without a prescription or skipping a recommended course, might hasten the emergence of resistance. Shigella infections have historically received excessive antibiotic treatment, which has put pressure on the bacteria to evolve resistance.

Vaccine Development Challenges

The nature of the bacteria and the sickness they cause make developing a vaccine for Shigella infections difficult. Although there has been progress, these difficulties have increased the difficulty of developing efficient vaccinations. On the basis of their surface antigens, Shigella bacteria are classified into various serotypes. It is difficult to develop a vaccine that offers comprehensive protection against all serotypes because immunization to one serotype may not offer cross-protection against another.

It has proved challenging to develop long-lasting immunity following natural infection or immunization. Some vaccinations have demonstrated a limited shelf life in terms of promoting protective immunity, necessitating replenishment shots to be effective.

Segment Analysis

The global shigella infections market is segmented based on drug class, type, route of administration, distribution channel, and region.

Increasing Prevalence of Shigella Sonnei Infection

Men who have intercourse with other men (MSM) are sexually susceptible to shigellosis, which is a serious digestive disease. Shigella sonnei is the source of this condition. Azithromycin and ciprofloxacin, two medications that the World Health Organization recommends as first-line therapies, are frequently resistant to several drugs in S. sonnei. Antibiotic-resistant Shigella sonnei is the primary cause of bacillary dysentery in high-income nations.

For instance, in response to an extraordinary rise in cases of Shigella sonnei infection and travel history to Cabo Verde, the Netherlands opened an event in EpiPulse, a restricted communications platform run by ECDC, in November 2022. Travelers returning from Cabo Verde had been infected with Shigella sonnei in numerous EU/EEA countries, the UK, and the US by the end of 2022. In addition, each year, the UK Health Security Agency (UKHSA) receives notifications of about 1650 cases of shigellosis, with S. sonnei being the most often found species.

Geographical Penetration

Advanced Healthcare Infrastructure and Active Major Players

North America has been a dominant force in the global shigella infections market. Shigellosis cases that have been recorded through national surveillance systems have increased, according to the Centers for Disease Control and Prevention (CDC). XDR strains were responsible for 5% of Shigella infections reported to the CDC in 2022 as opposed to 0% in 2015.

Limited antibiotic therapy options are available to clinicians caring for individuals infected with XDR strains. The germs Shigella are very contagious. Antibiotic resistance genes can be transferred from XDR Shigella strains to other intestinal bacteria. Aware of these potentially serious public health issues, the Centers for Disease Control and Prevention (CDC) urges medical professionals to be watchful in spotting and reporting suspected XDR Shigella infection cases to their regional or state health departments as well as informing patients and communities at higher risk about prevention and transmission.

In the United States, shigellosis, an acute enteric infection, is a significant contributor to both domestically acquired and travel-related bacterial diarrhea. Azithromycin, ciprofloxacin, or ceftriaxone are suggested empiric antimicrobial medications in the United States. For strains that are vulnerable, other therapies like ampicillin or TMP-SMX are advised.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global shigella infections market. Spending for research, therapies, and preventive plans for other infectious diseases including Shigella infections may have been affected by the pandemic's priority for global health spending.

People's ability to seek medical assistance for a variety of illnesses, including Shigella, may have been impacted by the pandemic's effects on healthcare access, particularly in low-resource areas. The COVID-19 pandemic's emphasis on cleanliness and handwashing may have indirectly helped avoid Shigella infections by encouraging communities to adopt better hygiene.

Russia-Ukraine War Impact Analysis

Basic services including the provision of clean water, sanitary conditions, and garbage disposal can be disrupted by conflicts. Shigellosis and other waterborne illnesses are more likely to spread when there is insufficient access to clean water and sanitary facilities. Due to the emphasis on wounds and stress associated with conflict, healthcare services may be disrupted.

During these periods, routine healthcare services, such as disease surveillance, can be neglected, which could result in underreporting and a delay in responding to infectious disease outbreaks. Conflict-related population displacement can result in overcrowded and unhealthy circumstances in refugee camps or other makeshift communities. These circumstances foster an atmosphere that is favorable for the spread of infectious diseases, such as infections caused by shigella caused by polluted water and poor hygiene.

By Type

  • Dysenteriae
  • Flexneri
  • Boydii
  • Sonnei

By Drug Class

  • Ciprofloxacin
  • Azithromycin
  • Others

By Route of Administration

  • Injectable
  • Oral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, the University of Maryland School of Medicine (UMSOM) in Baltimore and the Chief of Adult Clinical Studies at UMSOM's Center for Vaccine Development and Global Health (CVD) both announced the successful, full enrollment of Intralytix, Inc.'s Phase 1 clinical trial. ShigActive, a phage therapy product from Intralytix intended to prevent or lessen the severity of Shigella infections, is the subject of a clinical investigation to evaluate its safety. The National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, is contributing money to the trial.

Competitive Landscape

The major global players in the market include: Emergent BioSolutions, Inc., Pfizer, Inc., Aurobindo Pharma, LimmaTech Biologics AG, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Mylan N.V., Lupin Limited, Sun Pharmaceutical Industries Ltd., and Zydus Cadila.

Why Purchase the Report?

  • To visualize the global shigella infections market segmentation based on drug class, type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Shigella Infections market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global shigella infections market report would provide approximately 77 tables, 79 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Shigella Infections
      • 4.1.1.2. Vaccine Development
      • 4.1.1.3. Increasing Need to Develop New Antibiotics
      • 4.1.1.4. Awareness and Education
    • 4.1.2. Restraints
      • 4.1.2.1. Antibiotic Resistance
      • 4.1.2.2. Vaccine Development Challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Ciprofloxacin*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Azithromycin
  • 7.4. Others

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Dysenteriae*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Flexneri
  • 8.4. Boydii
  • 8.5. Sonnei

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Injectable*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Oral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Emergent BioSolutions, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Pfizer, Inc.
  • 13.3. Aurobindo Pharma
  • 13.4. LimmaTech Biologics AG
  • 13.5. Teva Pharmaceutical Industries Ltd.
  • 13.6. Fresenius Kabi AG
  • 13.7. Mylan N.V.
  • 13.8. Lupin Limited
  • 13.9. Sun Pharmaceutical Industries Ltd.
  • 13.10. Zydus Cadila

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us